Compare SELF & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SELF | CTSO |
|---|---|---|
| Founded | 1983 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.7M | 45.9M |
| IPO Year | N/A | N/A |
| Metric | SELF | CTSO |
|---|---|---|
| Price | $5.05 | $0.69 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | 49.2K | ★ 126.1K |
| Earning Date | 11-07-2025 | 11-13-2025 |
| Dividend Yield | ★ 5.86% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | $12,733,279.00 | ★ $36,979,520.00 |
| Revenue This Year | $1.59 | $9.51 |
| Revenue Next Year | $1.62 | $24.40 |
| P/E Ratio | $32.13 | ★ N/A |
| Revenue Growth | 3.36 | ★ 23.89 |
| 52 Week Low | $4.73 | $0.60 |
| 52 Week High | $5.89 | $1.61 |
| Indicator | SELF | CTSO |
|---|---|---|
| Relative Strength Index (RSI) | 57.28 | 47.73 |
| Support Level | $4.95 | $0.61 |
| Resistance Level | $5.18 | $0.77 |
| Average True Range (ATR) | 0.13 | 0.06 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 90.91 | 53.86 |
Global Self Storage Inc is a self-administered and self-managed REIT that owns, operates, manages, acquires, develops, and redevelops self-storage properties. The company's self-storage properties are designed to offer affordable, easily accessible, and secure storage space for residential and commercial customers. It has one segment of Rental operations. Through its wholly-owned subsidiaries, the company owns and/or manages close to thirteen self-storage properties in Connecticut, Illinois, Indiana, New York, Ohio, Pennsylvania, South Carolina, and Oklahoma.
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.